PF-Atlas › Clinical Trials › NCT05119972
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
ZSP1603 · Phase 1
Registry ID
NCT05119972
Phase
Phase 1
Status
Completed
Drug / intervention
ZSP1603
Sponsor
Guangdong Raynovent Biotech Co., Ltd
Start
2021-10-21
Enrollment
15
Locations
1
About this trial
This study was divided into two parts. The first part was a dose escalation study: a open label dose escalation design was used to evaluate the safety, tolerance and pharmacokinetic characteristics of ZSP1603 in IPF patients. The second part was a randomized double-blind placebo-controlled design was used to preliminatively investigate the efficacy and safety of ZSP1603 in the treatment of IPF at the target dose.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05119972 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.